Liraglutide and Not Lifestyle Intervention Reduces Soluble CD163 After Comparable Weight Loss in Obese Participants with Prediabetes or Type 2 Diabetes Mellitus

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2024 Apr 29

PMID 38685051

Authors

Helene Grannes

Thor Ueland

Paola Simeone

Rossella Liani

Maria Teresa Guagnano

Pal Aukrust

Annika E Michelsen

Kare Birkeland

Augusto Di Castelnuovo

Francesco Cipollone

Agostino Consoli

Bente Halvorsen

Ida Gregersen

Francesca Santilli

Affiliations

Soon will be listed here.

Abstract

Background: The GLP-1 receptor agonist liraglutide is used to treat hyperglycemia in type 2 diabetes but is also known to induce weight loss, preserve the beta cell and reduce cardiovascular risk. The mechanisms underlying these effects are however still not completely known. Herein we explore the effect of liraglutide on markers of immune cell activity in a population of obese individuals with prediabetes or newly diagnosed type 2 diabetes mellitus.

Method: Plasma levels of the monocyte/macrophage markers, soluble (s)CD163 and sCD14, the neutrophil markers myeloperoxidase (MPO) and neutrophil gelatinase-associated lipocalin (NGAL),the T-cell markers sCD25 and T-cell immunoglobulin mucin domain-3 (sTIM-3) and the inflammatory marker TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) were measured by enzyme-linked immunosorbent assays in obese individuals with prediabetes or diabetes diagnosed within the last 12 months, prior to and after comparable weight loss achieved with lifestyle changes (n = 20) or liraglutide treatment (n = 20), and in healthy subjects (n = 13).

Results: At baseline, plasma levels of the macrophage marker sCD163, and the inflammatory marker LIGHT were higher in cases as compared to controls. Plasma levels of sCD14, NGAL, sTIM-3 and sCD25 did not differ at baseline between patients and controls. After weight reduction following lifestyle intervention or liraglutide treatment, sCD163 decreased significantly in the liraglutide group vs. lifestyle (between-group difference p = 0.023, adjusted for visceral adipose tissue and triglycerides basal values). MPO and LIGHT decreased significantly only in the liraglutide group (between group difference not significant). Plasma levels of MPO and in particular sCD163 correlated with markers of metabolic dysfunction and inflammation. After weight loss, only sCD163 showed a trend for decreased levels during OGTT, both in the whole cohort as in those of liraglutide vs lifestyle group.

Conclusion: Weight loss following treatment with liraglutide was associated with reduced circulating levels of sCD163 when compared to the same extent of weight loss after lifestyle changes. This might contribute to reduced cardiometabolic risk in individuals receiving treatment with liraglutide.

Citing Articles

The CD163/TWEAK/Fn14 axis: A potential therapeutic target for alleviating inflammatory bone loss.

Qian J, Ma Y, Huang X, Li X, Xu Y, Liu Z J Orthop Translat. 2024; 49:82-95.

PMID: 39430128 PMC: 11488420. DOI: 10.1016/j.jot.2024.09.002.

References

Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X . The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Am J Clin Nutr. 2023; 118(3):614-626. DOI: 10.1016/j.ajcnut.2023.04.017. View

Balestrieri M, Rizzo M, Barbieri M, Paolisso P, DOnofrio N, Giovane A . Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes. 2014; 64(4):1395-406. DOI: 10.2337/db14-1149. View

Guarnotta V, Bianco M, Vigneri E, Panto F, Lo Sasso B, Ciaccio M . Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2021; 31(11):3193-3201. DOI: 10.1016/j.numecd.2021.07.015. View

van der Zalm I, van der Valk E, Wester V, Nagtzaam N, van Rossum E, Leenen P . Obesity-associated T-cell and macrophage activation improve partly after a lifestyle intervention. Int J Obes (Lond). 2020; 44(9):1838-1850. DOI: 10.1038/s41366-020-0615-6. View

Parkner T, Sorensen L, Nielsen A, Fischer C, Bibby B, Nielsen S . Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia. 2012; 55(6):1856-62. DOI: 10.1007/s00125-012-2533-1. View

Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X . The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflammation. 2019; 16(1):242. PMC: 6883580. DOI: 10.1186/s12974-019-1638-6. View

Fjeldborg K, Christiansen T, Bennetzen M, Moller H, Pedersen S, Richelsen B . The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity (Silver Spring). 2013; 21(12):2437-43. DOI: 10.1002/oby.20376. View

von Scholten B, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J . Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab. 2017; 19(6):901-905. DOI: 10.1111/dom.12884. View

Retnakaran R, Qi Y, Goran M, Hamilton J . Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med. 2009; 26(12):1198-203. DOI: 10.1111/j.1464-5491.2009.02841.x. View

10.

Semnani-Azad Z, Mejia S, Connelly P, Bazinet R, Retnakaran R, Jenkins D . The association of soluble CD163, a novel biomarker of macrophage activation, with type 2 diabetes mellitus and its underlying physiological disorders: A systematic review. Obes Rev. 2021; 22(9):e13257. DOI: 10.1111/obr.13257. View

11.

Chen Q, Chen S, Dai Y, Wang X, Ding F, Zhang R . Serum MPO levels and activities are associated with angiographic coronary atherosclerotic plaque progression in type 2 diabetic patients. BMC Cardiovasc Disord. 2022; 22(1):496. PMC: 9677674. DOI: 10.1186/s12872-022-02953-7. View

12.

Moller H . Soluble CD163. Scand J Clin Lab Invest. 2011; 72(1):1-13. DOI: 10.3109/00365513.2011.626868. View

13.

Simeone P, Liani R, Tripaldi R, Di Castelnuovo A, Guagnano M, Tartaro A . Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients. 2018; 10(12). PMC: 6315606. DOI: 10.3390/nu10121872. View

14.

Pedrosa M, Franco D, Gieremek H, Vidal C, Bronzeri F, de Cassia Rocha A . GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?. Curr Atheroscler Rep. 2022; 24(11):867-884. DOI: 10.1007/s11883-022-01062-2. View

15.

Wang Q, Xie Z, Zhang W, Zhou J, Wu Y, Zhang M . Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance. Diabetes. 2014; 63(12):4172-85. PMC: 4238009. DOI: 10.2337/db14-0026. View

16.

Hogan A, Gaoatswe G, Lynch L, Corrigan M, Woods C, OConnell J . Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2013; 57(4):781-4. DOI: 10.1007/s00125-013-3145-0. View

17.

Zanni M, Burdo T, Makimura H, Williams K, Grinspoon S . Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf). 2011; 77(3):385-90. PMC: 3660104. DOI: 10.1111/j.1365-2265.2011.04284.x. View

18.

Ying W, Lee Y, Dong Y, Seidman J, Yang M, Isaac R . Expansion of Islet-Resident Macrophages Leads to Inflammation Affecting β Cell Proliferation and Function in Obesity. Cell Metab. 2019; 29(2):457-474.e5. PMC: 6701710. DOI: 10.1016/j.cmet.2018.12.003. View

19.

Mahat R, Singh N, Rathore V . Association of myeloperoxidase with cardiovascular disease risk factors in prediabetic subjects. Diabetes Metab Syndr. 2019; 13(1):396-400. DOI: 10.1016/j.dsx.2018.10.016. View

20.

Simeone P, Tripaldi R, Michelsen A, Ueland T, Liani R, Ciotti S . Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss. Cardiovasc Diabetol. 2022; 21(1):36. PMC: 8917620. DOI: 10.1186/s12933-022-01469-w. View